To evaluate the use of immune checkpoint inhibitors (ICIs) for lung cancer in Morocco and assess their clinical and economic implications, particularly focusing on access and resource allocation.
Key Findings:
158 patients treated with ICIs were included, representing 5% of eligible lung cancer patients.
Median age was 62.48 years; 82% were male.
12-month overall survival rate was 71.1%; median overall survival was 17 months, indicating a significant clinical benefit.
Objective response rate was 40%; no significant survival differences among treatment types.
Interpretation:
ICIs show promising real-world outcomes in advanced lung cancer in Morocco, with survival rates comparable to higher-income countries despite economic constraints, highlighting the need for improved access.
Limitations:
High rate of missing PD-L1 status (34.2%) may affect treatment stratification and introduce bias.
Limited generalizability due to the study's focus on a single middle-income country.
Conclusion:
The study highlights the potential of ICIs in improving outcomes for lung cancer patients in Morocco, emphasizing the need for better access, resource allocation, and addressing economic barriers.
